Clinical Trial Data

The Children’s Oncology Group’s (COG) ANBL0032 was a landmark phase 3, randomized, multi-institutional, clinical trial1

Unituxin® has been studied in many clinical trials conducted by COG, the world's largest organization devoted exclusively to pediatric cancer research. The pivotal trial that led to FDA approval of Unituxin was COG’s ANBL0032 study, which showed that antibody therapy with Unituxin (known as ch14.18 during the study), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) , and retinoic acid (RA) was associated with a significantly improved outcome compared with standard therapy in patients with high-risk neuroblastoma.1,2

Explore the robust ANBL0032 clinical trial data:

See the long-term survival data

Learn how the study was conducted

Review the results and efficacy of Unituxin

See the long-term survival data

Learn how the study was conducted

ANBL0032 study overview

Study design: ANBL0032 was a randomized, open-label, multi-institutional trial to determine whether adding Unituxin, GM-CSF, and IL-2 to standard retinoic acid (RA) therapy after induction chemotherapy, surgery, autologous stem cell transplant, and radiation therapy improved outcomes in patients with high-risk neuroblastoma.1

Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive 6 cycles of standard therapy (RA alone) or 6 cycles of the Unituxin antibody therapy regimen with alternating GM-CSF and IL-2.1,3

← Swipe to view results →

*Randomization occurred between day 50 and day 77 after autologous stem cell transplantation.3

Efficacy end points: Event-free survival (EFS) and overall survival (OS) were compared between the Unituxin group and the standard-therapy group on an intention-to-treat basis.1,3

Results

Improved EFS compared with RA alone

Unituxin compared with standard treatment showed 2-year EFS rates of 66±5% vs 46±5% (P=0.01), respectively. EFS was defined as the time from randomization to the first occurrence of relapse, progressive disease, secondary malignancy, or death.1

2-year EFS rate in children with treatment-responsive high-risk neuroblastoma1

← Swipe to view results →

Significantly improved outcomes with the antibody therapy regimen vs RA alone led to an early termination of the randomized portion of the clinical trial, and all eligible patients were then nonrandomized to receive the Unituxin regimen.1

Long-term survival benefit at 5 years

The antibody therapy regimen demonstrated a significant long-term survival benefit in 226 eligible randomized patients as part of the extended follow-up of COG’s ANBL0032 randomized phase 3 trial, according to results published in Clinical Cancer Research.4

5-year EFS

5-year EFS was 57±4.7% for patients randomized to the Unituxin group (n=114) vs 46±5.1% for those randomized to the RA-only group (n=112; P=0.042).4

5-year EFS rate in children with treatment-responsive high-risk neuroblastoma4

← Swipe to view results →

5-year OS

5-year OS was 73% for patients randomized to the Unituxin group (n=114) vs 57% for those randomized to the RA-only group (n=112; P=0.045).4

video player graphic
MOA

Watch the video to see how Unituxin works.

Safety Profile
Safety Profile

Review the well-established safety profile.

References: 1. Yu AL, Gilman AL, Ozkaynak MF, et al; the Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-1334. 2. Children’s Oncology Group website. About us. https://childrensoncologygroup.org/index.php/62-about-us/about-us. Accessed June 11, 2021. 3. Unituxin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2020. 4. Yu AL, Gilman AL, Ozkaynak MF, et al. Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: Children’s Oncology Group study ANBL0032. Clin Cancer Res. 2021;27(8):2179-2189.

Indication

Unituxin is used to treat children with high-risk neuroblastoma who have had some success with prior first-line treatments. Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) are part of the treatment regimen with Unituxin.

Important Safety Information for Unituxin
  • Boxed WARNING
  • Serious Infusion Reactions
    • Unituxin can cause serious and potentially life-threatening infusion reactions. These include excess fluid in tissue, noisy or difficult breathing, a feeling of narrowing in the throat, rash, and low blood pressure.
    • Tell your healthcare professional right away if you notice any of the following on the day of, or the day after, the infusion: facial or lip swelling, rash, difficulty breathing, lightheadedness, or dizziness. Patients who experience severe infusion reactions should stop receiving treatment with Unituxin.
  •  
  • Neurotoxicity
    • Unituxin causes serious neurologic adverse reactions including severe neuropathic pain (nerve pain) and peripheral neuropathy (weakness, pain and/or numbness in hands, feet, legs or arms).
    • Severe neuropathic pain occurs in the majority of patients. Pain medication given prior to, during, and for 2 hours following treatment can help manage the pain.
    • Tell your healthcare professional about severe or worsening pain and signs and symptoms of neuropathy such as numbness, tingling, burning, or weakness experienced during treatment with Unituxin. Depending on the severity of pain, patients may need to stop treatment.

CONTRAINDICATIONS

Patients who are allergic to dinutuximab should not take Unituxin.

WARNINGS AND PRECAUTIONS

Serious Infusion Reactions

  • In a clinical study, 35 (26%) patients taking Unituxin experienced severe (Grade 3 or 4) infusion reactions. Serious infusion reactions included swelling of the face and upper airway, difficult or abnormal breathing, bronchospasm, rash and hives, and low blood pressure. Urgent intervention included blood pressure support, bronchodilator therapy, corticosteroids, infusion rate reduction, infusion interruption, or permanent discontinuation of Unituxin.
  • Infusion reactions generally happen during or within 24 hours after treatment with Unituxin. Tell your healthcare professional right away if you notice any signs or symptoms of serious infusion reactions, including facial or lip swelling, rash, difficulty breathing, lightheadedness, or dizziness, that occur during or within 24 hours following infusion. Your healthcare professional will decide whether treatment should be stopped temporarily or permanently.

Neurotoxicity

  • Pain:
    • Your healthcare professional will administer medication before, during, and after treatment to help manage pain. Tell your healthcare professional right away about any severe or worsening pain.
    • In a clinical study, 114 (85%) patients taking Unituxin experienced pain despite pre-treatment with pain medicine including morphine sulfate infusion. Severe (Grade 3) pain occurred in 68 (51%) patients taking Unituxin compared to 5 (5%) patients who were not taking Unituxin. Pain typically occurred during the Unituxin infusion and was most commonly reported as stomach pain, generalized pain, pain in the arms or legs, back pain, nerve pain, muscle and bone pain of the chest, and joint pain.
    • If severe pain is experienced, your healthcare professional may reduce the speed at which Unituxin is given. Unituxin may be stopped if pain is not adequately controlled through medical intervention.
  • Peripheral Neuropathy:
    • Symptoms of neuropathy (may include numbness, tingling, burning), or weakness. Report any signs or symptoms of neuropathy immediately to your healthcare provider.
    • In a clinical study, severe (Grade 3) peripheral sensory neuropathy occurred in 2 (1%) patients and severe peripheral motor neuropathy occurred in 2 (1%) patients taking Unituxin compared to zero patients who were not taking Unituxin.
    • Treatment with Unituxin may need to be permanently discontinued in patients with Grade 2 peripheral motor neuropathy, Grade 3 sensory neuropathy that interferes with daily activities for more than 2 weeks, or Grade 4 sensory neuropathy.
  • Neurological Disorders of the Eye:
    • Neurological disorders of the eye can be serious. Tell your healthcare professional immediately if you experience blurred vision, sensitivity to light, drooping of the upper eyelid, double vision, optic disc swelling, or fixed or unequal pupil size as these can be signs and symptoms of a neurological disorder of the eye. Patients who experience neurological disorders of the eye may need to have the Unituxin dose reduced or permanently stopped.
    • In clinical studies, neurological disorders of the eye experienced by 2 or more patients treated with Unituxin included blurred vision, sensitivity to light, dilated pupils, an inability to move the eyelid, fixed or unequal pupils, optic nerve disorder, drooping of the eyelid, and swelling.
  • Prolonged Urinary Retention:
    • Urinary retention (inability to completely empty the bladder) that persists for weeks to months after stopping opioids has occurred in patients treated with Unituxin. Report to your healthcare provider persistent urinary retention that does not resolve after having stopped opioid therapy. If you experience prolonged urinary retention, your healthcare professional will decide whether treatment should be stopped.
  • Transverse Myelitis:
    • Transverse myelitis has occurred in patients treated with Unituxin. Symptoms may include weakness, tingling or burning sensation, reduced sensation, or inability to control urine. Report signs or symptoms of transverse myelitis immediately to your healthcare provider. Your healthcare professional will determine if you have transverse myelitis and stop treatment as necessary.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS):
    • RPLS is swelling in the back part of the brain. It has occurred in patients treated with Unituxin. Symptoms may include severe headache, high blood pressure, change in vision, feeling drowsy or tired, or seizures (fits). Report signs or symptoms immediately to your healthcare provider. Unituxin may be stopped in patients with signs and symptoms of RPLS.

Capillary Leak Syndrome

  • Capillary leak syndrome is a potentially life-threatening condition in which fluid and proteins leak out of tiny blood vessels and flow into surrounding tissue. This leads to dangerously low blood pressure. If severe capillary leak syndrome is experienced, the speed at which Unituxin is given may need to be interrupted, reduced, or permanently stopped.
  • Signs and symptoms of capillary leak syndrome include swelling of the arms, legs, and other parts of the body; shock; lightheadedness; weakness; fatigue; nausea; and rapid drop in blood pressure. Immediately report any signs or symptoms of capillary leak syndrome to your healthcare professional.
  • In a clinical study, severe (Grades 3 to 5) capillary leak syndrome occurred in 31 (23%) patients taking Unituxin and in no patients who were not taking Unituxin.

Low Blood Pressure

  • In a clinical study, 22 (16%) patients taking Unituxin experienced severe (Grade 3 or 4) low blood pressure. Fluids will be given by your healthcare professional prior to treatment with Unituxin. Blood pressure should be watched closely during Unituxin treatment. Tell your healthcare professional right away if you experience any changes in breathing, dizziness or lightheadedness, fainting, or dehydration (symptoms may include unusual thirst, urinating less often than usual, dark colored urine, dry skin, or tiredness). Patients who get low blood pressure may need to have the speed at which Unituxin is given reduced or permanently stopped.

Infection

  • In a clinical study, 17 (13%) patients experienced severe (Grade 3 or 4) bacteremia that required urgent intervention, and 24 (18%) patients experienced sepsis. Closely monitor for signs and symptoms of systemic infection such as fever or tiredness. Tell your healthcare professional if you notice any signs of an infection.
  • Patients who develop systemic infection will need to temporarily stop treatment with Unituxin until the infection resolves.

Bone Marrow Suppression

  • Patients taking Unituxin may have slow blood clotting. This is due to a lowering of the number of platelets in the blood. Unituxin may also cause low red blood cell count (anemia) and low white blood cell count. This may make patients more likely to develop an infection.
  • In a clinical study, severe (Grade 3 or 4) platelet deficiency (39% vs. 25%), low red blood cell count (34% vs. 16%), low white blood cell count (34% vs. 13%), and fever along with a low white blood cell count (4% vs. 0 patients) occurred more commonly in patients who were taking Unituxin than in patients who were not taking Unituxin.

Electrolyte Abnormalities

  • In a clinical study, electrolyte abnormalities occurring in at least 25% of patients who received Unituxin included low levels of sodium, low levels of potassium, and low levels of calcium in the bloodstream. Your healthcare professional will monitor these levels. Tell your healthcare professional about any seizures; a feeling that the heart is beating too hard or too fast, skipping a beat, or fluttering; or muscle cramping.

Atypical Hemolytic Uremic Syndrome

  • Patients taking Unituxin may experience kidney problems, electrolyte abnormalities, low red blood cell count, or high blood pressure. Patients who experience these side effects may need to permanently stop treatment with Unituxin. Tell your healthcare professional about any fatigue, dizziness, fainting, extreme skin paleness, swelling, less urine output than normal, or blood in the urine.

Tell your healthcare professional if you are pregnant before taking Unituxin.

  • Unituxin may cause harm to an unborn child. Women who are taking Unituxin should use effective birth control measures during treatment and for 2 months after the last dose of Unituxin.

COMMON SERIOUS ADVERSE REACTIONS

The following is a list of the most common serious adverse reactions seen in 5% or more of patients taking Unituxin:

  • Infections
  • Infusion reactions
  • Low levels of potassium in the blood
  • Low blood pressure
  • Pain
  • Fever
  • Capillary leak syndrome (a potentially life-threatening condition in which fluid and proteins leak out of tiny blood vessels and flow into surrounding tissue, leading to dangerously low blood pressure)

COMMON ADVERSE REACTIONS

The following is a list of the most common adverse reactions seen in 25% or more of patients taking Unituxin:

  • Pain
  • Fever
  • Slow blood clotting
  • Reduced ability to fight infections (low levels of white blood cells of various kinds)
  • Infusion reactions
  • Low blood pressure
  • Low levels of sodium in the blood
  • Increased levels of the enzyme alanine aminotransferase in the blood
  • Low red blood cell count
  • Vomiting
  • Diarrhea
  • Low levels of potassium in the blood
  • Capillary leak syndrome
  • Hives
  • Low levels of albumin in the blood
  • Increased levels of the enzyme aspartate aminotransferase
  • Low levels of calcium in the blood

The following side effects have also been observed in patients taking Unituxin after approval: prolonged urinary retention (inability to completely empty the bladder), transverse myelitis, and reversible posterior leukoencephalopathy (swelling in the back part of the brain).

Tell your healthcare professional about any side effect seen during treatment with Unituxin. These are not all the possible side effects of Unituxin. For more information, talk to your healthcare professional.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

UTXISIdtcMAR17

Please see Full Prescribing Information, including Boxed WARNING, for Unituxin.

UNITUXIN® (dinutuximab) INJECTION, FOR INTRAVENOUS USE
Indication

Unituxin is used to treat children with high-risk neuroblastoma who have had some success with prior first-line treatments. Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) are part of the treatment regimen with Unituxin.

Important Safety Information for Unituxin
  • Boxed WARNING
  • Serious Infusion Reactions
    • Unituxin can cause serious and potentially life-threatening infusion reactions. These include excess fluid in tissue, noisy or difficult breathing, a feeling of narrowing in the throat, rash, and low blood pressure.
    • Tell your healthcare professional right away if you notice any of the following on the day of, or the day after, the infusion: facial or lip swelling, rash, difficulty breathing, lightheadedness, or dizziness. Patients who experience severe infusion reactions should stop receiving treatment with Unituxin.
  •  
  • Neurotoxicity
    • Unituxin causes serious neurologic adverse reactions including severe neuropathic pain (nerve pain) and peripheral neuropathy (weakness, pain and/or numbness in hands, feet, legs or arms).
    • Severe neuropathic pain occurs in the majority of patients. Pain medication given prior to, during, and for 2 hours following treatment can help manage the pain.
    • Tell your healthcare professional about severe or worsening pain and signs and symptoms of neuropathy such as numbness, tingling, burning, or weakness experienced during treatment with Unituxin. Depending on the severity of pain, patients may need to stop treatment.

CONTRAINDICATIONS

Patients who are allergic to dinutuximab should not take Unituxin.

WARNINGS AND PRECAUTIONS

Serious Infusion Reactions

  • In a clinical study, 35 (26%) patients taking Unituxin experienced severe (Grade 3 or 4) infusion reactions. Serious infusion reactions included swelling of the face and upper airway, difficult or abnormal breathing, bronchospasm, rash and hives, and low blood pressure. Urgent intervention included blood pressure support, bronchodilator therapy, corticosteroids, infusion rate reduction, infusion interruption, or permanent discontinuation of Unituxin.
  • Infusion reactions generally happen during or within 24 hours after treatment with Unituxin. Tell your healthcare professional right away if you notice any signs or symptoms of serious infusion reactions, including facial or lip swelling, rash, difficulty breathing, lightheadedness, or dizziness, that occur during or within 24 hours following infusion. Your healthcare professional will decide whether treatment should be stopped temporarily or permanently.

Neurotoxicity

  • Pain:
    • Your healthcare professional will administer medication before, during, and after treatment to help manage pain. Tell your healthcare professional right away about any severe or worsening pain.
    • In a clinical study, 114 (85%) patients taking Unituxin experienced pain despite pre-treatment with pain medicine including morphine sulfate infusion. Severe (Grade 3) pain occurred in 68 (51%) patients taking Unituxin compared to 5 (5%) patients who were not taking Unituxin. Pain typically occurred during the Unituxin infusion and was most commonly reported as stomach pain, generalized pain, pain in the arms or legs, back pain, nerve pain, muscle and bone pain of the chest, and joint pain.
    • If severe pain is experienced, your healthcare professional may reduce the speed at which Unituxin is given. Unituxin may be stopped if pain is not adequately controlled through medical intervention.
  • Peripheral Neuropathy:
    • Symptoms of neuropathy (may include numbness, tingling, burning), or weakness. Report any signs or symptoms of neuropathy immediately to your healthcare provider.
    • In a clinical study, severe (Grade 3) peripheral sensory neuropathy occurred in 2 (1%) patients and severe peripheral motor neuropathy occurred in 2 (1%) patients taking Unituxin compared to zero patients who were not taking Unituxin.
    • Treatment with Unituxin may need to be permanently discontinued in patients with Grade 2 peripheral motor neuropathy, Grade 3 sensory neuropathy that interferes with daily activities for more than 2 weeks, or Grade 4 sensory neuropathy.
  • Neurological Disorders of the Eye:
    • Neurological disorders of the eye can be serious. Tell your healthcare professional immediately if you experience blurred vision, sensitivity to light, drooping of the upper eyelid, double vision, optic disc swelling, or fixed or unequal pupil size as these can be signs and symptoms of a neurological disorder of the eye. Patients who experience neurological disorders of the eye may need to have the Unituxin dose reduced or permanently stopped.
    • In clinical studies, neurological disorders of the eye experienced by 2 or more patients treated with Unituxin included blurred vision, sensitivity to light, dilated pupils, an inability to move the eyelid, fixed or unequal pupils, optic nerve disorder, drooping of the eyelid, and swelling.
  • Prolonged Urinary Retention:
    • Urinary retention (inability to completely empty the bladder) that persists for weeks to months after stopping opioids has occurred in patients treated with Unituxin. Report to your healthcare provider persistent urinary retention that does not resolve after having stopped opioid therapy. If you experience prolonged urinary retention, your healthcare professional will decide whether treatment should be stopped.
  • Transverse Myelitis:
    • Transverse myelitis has occurred in patients treated with Unituxin. Symptoms may include weakness, tingling or burning sensation, reduced sensation, or inability to control urine. Report signs or symptoms of transverse myelitis immediately to your healthcare provider. Your healthcare professional will determine if you have transverse myelitis and stop treatment as necessary.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS):
    • RPLS is swelling in the back part of the brain. It has occurred in patients treated with Unituxin. Symptoms may include severe headache, high blood pressure, change in vision, feeling drowsy or tired, or seizures (fits). Report signs or symptoms immediately to your healthcare provider. Unituxin may be stopped in patients with signs and symptoms of RPLS.

Capillary Leak Syndrome

  • Capillary leak syndrome is a potentially life-threatening condition in which fluid and proteins leak out of tiny blood vessels and flow into surrounding tissue. This leads to dangerously low blood pressure. If severe capillary leak syndrome is experienced, the speed at which Unituxin is given may need to be interrupted, reduced, or permanently stopped.
  • Signs and symptoms of capillary leak syndrome include swelling of the arms, legs, and other parts of the body; shock; lightheadedness; weakness; fatigue; nausea; and rapid drop in blood pressure. Immediately report any signs or symptoms of capillary leak syndrome to your healthcare professional.
  • In a clinical study, severe (Grades 3 to 5) capillary leak syndrome occurred in 31 (23%) patients taking Unituxin and in no patients who were not taking Unituxin.

Low Blood Pressure

  • In a clinical study, 22 (16%) patients taking Unituxin experienced severe (Grade 3 or 4) low blood pressure. Fluids will be given by your healthcare professional prior to treatment with Unituxin. Blood pressure should be watched closely during Unituxin treatment. Tell your healthcare professional right away if you experience any changes in breathing, dizziness or lightheadedness, fainting, or dehydration (symptoms may include unusual thirst, urinating less often than usual, dark colored urine, dry skin, or tiredness). Patients who get low blood pressure may need to have the speed at which Unituxin is given reduced or permanently stopped.

Infection

  • In a clinical study, 17 (13%) patients experienced severe (Grade 3 or 4) bacteremia that required urgent intervention, and 24 (18%) patients experienced sepsis. Closely monitor for signs and symptoms of systemic infection such as fever or tiredness. Tell your healthcare professional if you notice any signs of an infection.
  • Patients who develop systemic infection will need to temporarily stop treatment with Unituxin until the infection resolves.

Bone Marrow Suppression

  • Patients taking Unituxin may have slow blood clotting. This is due to a lowering of the number of platelets in the blood. Unituxin may also cause low red blood cell count (anemia) and low white blood cell count. This may make patients more likely to develop an infection.
  • In a clinical study, severe (Grade 3 or 4) platelet deficiency (39% vs. 25%), low red blood cell count (34% vs. 16%), low white blood cell count (34% vs. 13%), and fever along with a low white blood cell count (4% vs. 0 patients) occurred more commonly in patients who were taking Unituxin than in patients who were not taking Unituxin.

Electrolyte Abnormalities

  • In a clinical study, electrolyte abnormalities occurring in at least 25% of patients who received Unituxin included low levels of sodium, low levels of potassium, and low levels of calcium in the bloodstream. Your healthcare professional will monitor these levels. Tell your healthcare professional about any seizures; a feeling that the heart is beating too hard or too fast, skipping a beat, or fluttering; or muscle cramping.

Atypical Hemolytic Uremic Syndrome

  • Patients taking Unituxin may experience kidney problems, electrolyte abnormalities, low red blood cell count, or high blood pressure. Patients who experience these side effects may need to permanently stop treatment with Unituxin. Tell your healthcare professional about any fatigue, dizziness, fainting, extreme skin paleness, swelling, less urine output than normal, or blood in the urine.

Tell your healthcare professional if you are pregnant before taking Unituxin.

  • Unituxin may cause harm to an unborn child. Women who are taking Unituxin should use effective birth control measures during treatment and for 2 months after the last dose of Unituxin.

COMMON SERIOUS ADVERSE REACTIONS

The following is a list of the most common serious adverse reactions seen in 5% or more of patients taking Unituxin:

  • Infections
  • Infusion reactions
  • Low levels of potassium in the blood
  • Low blood pressure
  • Pain
  • Fever
  • Capillary leak syndrome (a potentially life-threatening condition in which fluid and proteins leak out of tiny blood vessels and flow into surrounding tissue, leading to dangerously low blood pressure)

COMMON ADVERSE REACTIONS

The following is a list of the most common adverse reactions seen in 25% or more of patients taking Unituxin:

  • Pain
  • Fever
  • Slow blood clotting
  • Reduced ability to fight infections (low levels of white blood cells of various kinds)
  • Infusion reactions
  • Low blood pressure
  • Low levels of sodium in the blood
  • Increased levels of the enzyme alanine aminotransferase in the blood
  • Low red blood cell count
  • Vomiting
  • Diarrhea
  • Low levels of potassium in the blood
  • Capillary leak syndrome
  • Hives
  • Low levels of albumin in the blood
  • Increased levels of the enzyme aspartate aminotransferase
  • Low levels of calcium in the blood

The following side effects have also been observed in patients taking Unituxin after approval: prolonged urinary retention (inability to completely empty the bladder), transverse myelitis, and reversible posterior leukoencephalopathy (swelling in the back part of the brain).

Tell your healthcare professional about any side effect seen during treatment with Unituxin. These are not all the possible side effects of Unituxin. For more information, talk to your healthcare professional.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

UTXISIdtcMAR17

Please see Full Prescribing Information, including Boxed WARNING, for Unituxin.